Why the study?
The study aimed to compare shortened (≤3 months) dual antiplatelet therapy with longer DAPT regimens in diabetic patients undergoing percutaneous coronary interventions.
Does shortened dual antiplatelet therapy (≤3 months) reduce net adverse clinical events compared to longer therapy in diabetic patients undergoing percutaneous coronary interventions?
Does shortened dual antiplatelet therapy (≤3 months) reduce net adverse clinical events compared to longer therapy in diabetic patients undergoing percutaneous coronary interventions?
Answers are grounded in this paper and cite their sources.
Shortened dual antiplatelet therapy (≤3 months) is associated with a lower incidence of net adverse clinical events compared to longer DAPT in diabetic patients undergoing PCI, suggesting it is a safe and feasible option.
Aim of our systematic review and meta-analysis is to compare shortened (≤3 months) dual antiplatelet therapy (DAPT) with longer DAPT in diabetic patients undergoing percutaneous coronary interventions.We systematically screened 3 major databases (MEDLINE, Cochrane Central Register of Controlled Trials, and Scopus) searching for randomized-controlled trials or subanalyses of them, which compared shortened DAPT (S-DAPT) with longer DAPT regimens of DAPT. Primary end point of systematic review and meta-analysis is the net adverse clinical events (NACE), and secondary are major adverse cardiac events (MACE), mortality, bleedings, myocardial infarction, and stent thrombosis. Subgroup analyses included studies using only ticagrelor-based regimens and 3-month duration of DAPT.A total of 8 studies and 12,665 patients were included in our analysis. Our meta-analysis met its primary end point because S-DAPT was associated significantly with a reduced risk ratio (RR) by 17% [RR: 0.83, 95% confidence intervals (CI), 0.72-0.96]. Nonsignificant difference among the rest end points was detected between the 2 groups. Subgroup analyses showed that ticagrelor-based regimens were associated with a significant reduction of mortality (RR: 0.67, 95% CI, 0.48-0.93) and 3-month DAPT reduced furtherly NACE by 27% (RR: 0.73, 95% CI, 0.60-0.89).In conclusion, our systematic review and meta-analysis showed that (i) S-DAPT was significantly associated with a lower incidence of NACE, (ii) ticagrelor-based S-DAPT was associated with decreased mortality rates, and (iii) the benefit of 3-month duration of DAPT achieved an even greater NACE reduction. Thus, S-DAPT could be considered as a safe and feasible option in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Apostolos et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: